The Science Behind Steadyline

What the research shows

Daily mood charting is clinically validated

Steadyline's tracking approach is grounded in the NIMH Life Chart Method (LCM) — a daily prospective mood charting framework developed by the National Institute of Mental Health and validated across hundreds of patients in multi-site studies.

Two landmark validation studies confirm that daily self-ratings closely track clinician assessments:

• Depression self-ratings correlated at r = −0.72 to −0.79 with the clinician-administered Inventory of Depressive Symptomatology (IDS-C) [Denicoff et al., 2000] [Born et al., 2014]
• Mania self-ratings correlated at r = 0.49 to 0.66 with the Young Mania Rating Scale (YMRS) — valid but weaker, for reasons explained in the limitations section below.
• Smartphone app-based life charts maintain equivalent validity to pen-and-paper versions [Schärer et al., 2015]

Sleep is the most reliable early warning signal

Of all the variables you can track, sleep has the strongest evidence base as a leading indicator of mood episode changes in bipolar disorder.

• Decreased sleep duration was the strongest predictor of next-day mania or hypomania in rapid-cycling patients tracked prospectively over 18 months [Leibenluft et al., 1996]
• Cross-correlation analyses of 59 bipolar outpatients showed mood typically changed the day after a sleep change — a decrease in sleep/bedrest by more than 3 hours often preceded hypomanic shifts; increases preceded depressive shifts [Bauer et al., 2006]
• Insomnia appears ~20 days before manic episodes and ~150 days before depression on average; hypersomnia emerges ~60 days before depression [Basquin et al., 2024]
• A 2025 study found within-night sleep variability predicted hypomania onset with sensitivity 0.94, specificity 0.80 [Ortiz et al., 2025]

This is why sleep is not an optional extra in Steadyline — it is the primary signal.

Tracking symptoms mapped to DSM-5 criteria

Every dimension Steadyline tracks — mood, energy, sleep, irritability, goal-directed activity — corresponds directly to the diagnostic criteria for manic, hypomanic, and major depressive episodes as defined in the DSM-5 [APA, 2013].

A key DSM-5 update (vs DSM-IV): increased energy and activity is now a required gate criterion alongside mood change for manic and hypomanic episodes [Phillips & Kupfer, 2013]. Steadyline tracks energy as a first-class metric because of this — not because it sounds good, but because DSM-5 says it belongs in the same tier as mood.

Clinician reports have a research basis

Steadyline can generate a structured PDF for your psychiatrist or therapist. This follows the pattern of the NIMH-LCM-p clinician format, which has been used in clinical trials to characterize episode frequency, severity, and duration — with findings varying significantly by treatment response [Denicoff et al., 2002].

The report maps your tracked data to DSM-5 symptom domains. A psychiatrist who receives it will see structured data they can integrate into their own clinical assessment — not a diagnosis, not a recommendation, but context.

Digital tracking is feasible and people actually stick with it

A common concern: will anyone actually use an app consistently? The evidence is reasonably encouraging:

• 48 bipolar patients tracked daily mood using the Mood Zoom app with adherence of 86.7% at 3 months and 81.9% at 12 months [Tsanas et al., 2016]
• A 28-day smartphone study completed ~91% of twice-daily mood prompts [Gershon et al., 2020]
• ChronoRecord, a digital mood charting tool, has been used by 609 patients over 20+ years — demonstrating that longitudinal digital tracking is not just a research curiosity [Bauer et al., 2023]

How the Stability Score works

Your Stability Score is a summary signal — a single number that compresses your recent mood, sleep, energy, and consistency into something at a glance. Here's exactly what goes into it:

• Mood variance — high variance (frequent swings) lowers the score; stability raises it
• Sleep regularity — irregular sleep timing and duration drag the score down
• Energy-mood alignment — when energy and mood diverge sharply, that signals instability
• Logging consistency — gaps in your log history are treated as unknown, not fine; the score reflects uncertainty when data is sparse

The score is not a clinical assessment. It is a personal signal calibrated to you — it improves when your patterns are steady, not when your mood is high. A calm, low-mood week scores better than a volatile high-mood week. Stability is the goal, not happiness.

The AI analysis in Steadyline uses your historical log data to surface patterns across mood, sleep, and energy. It can identify correlations (e.g., "your mood drops 2 days after sleep drops below 6 hours") but it does not generate diagnoses, medication recommendations, or clinical predictions.

Where the evidence has real limits

We want to be direct about this. An honest reading of the literature shows that mood tracking apps — including Steadyline — have meaningful limitations that you should know about.

Self-report fails during mania

This is the most critical limitation. A systematic review found that electronic self-monitoring is validated against clinical scales for depression in 6 out of 6 studies — but only 2 out of 7 studies showed robust validity for mania [Faurholt-Jepsen et al., 2016].

The reason is intuitive: during a manic episode, insight often deteriorates. People feel great, and their self-report reflects that feeling — not the clinical reality. This means Steadyline is more reliable as a depression and stability monitor than as a mania monitor.

Tracking alone does not reduce symptoms

The most recent meta-analysis of randomized controlled trials (2026) found that mood monitoring interventions do not significantly reduce depressive or manic symptoms compared to control conditions [Astill Wright et al., 2026].

Where benefits do appear, they are in: insight into personal patterns, treatment adherence, quality of life, and — when tracking is embedded within structured psychoeducation — modest symptom improvements. Tracking by itself is not a treatment.

Frequent tracking can worsen mood for some people

A small but real subset of users experience mood tracking negatively: increased rumination, anxiety about relapse, or frustration at persistent low ratings [de Angel et al., 2025]. Pooled prevalence of subjective mood worsening is estimated around 2%, though based on limited and heterogeneous data.

If you notice that daily logging is making you feel worse — more anxious, more fixated — that is a signal worth taking seriously. You can reduce logging frequency, log fewer dimensions, or take a break. Steadyline is a tool, not an obligation.

Most mental health apps have no clinical evidence

A review of top-returned apps for bipolar disorder found that only one app's efficacy was supported in a peer-reviewed study, and 32 apps lacked privacy policies entirely [Lagan et al., 2020]. A separate content quality review found fewer than 22% of bipolar apps provided a privacy policy, and only 1 of the most-used apps was actually developed for bipolar populations [Nicholas et al., 2015].

Steadyline is not a clinically validated medical device. It has not been through an RCT. What it is: an app built on published methodology (NIMH-LCM), with a clear privacy policy, tracking the variables that clinical research says actually matter.

Long-term clinical benefit is uncertain

Most smartphone monitoring studies run for 4 weeks to 12 months with small samples. The evidence on what happens at years 2, 3, or 5 of consistent tracking is limited. We don't know whether long-term tracking produces compounding insight or whether adherence (and usefulness) declines over time for most people [Faurholt-Jepsen et al., 2018].

What Steadyline is — and isn't

Mental health data is some of the most sensitive data that exists. We take that seriously. Your mood logs, medications, and notes are encrypted, stored locally by default, and never sold. See our Privacy Policy for details.

Citations verified through PubMed and PMC as of March 2026. If you're a researcher or clinician with feedback on this page, reach out — we want to get this right.